California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies. The Vivo Opportunity Fund is an evergreen public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results